Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986553 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| BMS-986553 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986553 | DRUG | Specified dose on specified days |
Inclusion Criteria: * SLE participants: Must have diagnosis of SLE defined as fulfilling the 2019 ACR/EULAR classification criteria of SLE. * IIM participants: Must have diagnosis of IIM defined as fulfilling the 2017 ACR/EULAR classification criteria for probable or definite IIM. * SSc participant...
Top 20 of 34 competitors
BMS-986553 is an investigational small molecule drug being developed by Bristol-Myers Squibb Company for systemic lupus erythematosus and other autoimmune conditions. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in a single early-stage trial that has not yet begun recruiting participants.
BMS-986553 is being studied for systemic lupus erythematosus, along with Sjogren's disease, rheumatoid arthritis, idiopathic inflammatory myopathies, systemic sclerosis, and lupus nephritis. These are the conditions listed in its ongoing clinical program. It is investigational, so it is not currently approved for any use, and its use is limited to research settings.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is developing BMS-986553. The company is the sponsor of the drug's clinical program in autoimmune diseases. The compound is a small molecule in Phase 1 development.
BMS-986553 is in Phase 1 clinical development. It is an investigational drug and is not FDA approved. The program consists of one Phase 1 trial that is not yet recruiting, with a planned enrollment of 60 participants. No trials of BMS-986553 have been completed.
BMS-986553 is being evaluated in one Phase 1 trial, NCT07873931, titled A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases. The trial is not yet recruiting and plans to enroll 60 participants across the United States, Belgium, France, Germany, the Netherlands, and Poland. It is an uncontrolled study open to adults 18 years and older.